DMAC vs IRM · $157.4M cap vs P/E 136, rev $6.15B
DiaMedica Therapeutics Inc (DMAC) versus Iron Mountain Incorporated (IRM) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Iron Mountain Incorporated (IRM) is a reit - specialty company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported IRM revenue for 2024-12-31 was $6.15B. Net income was $183.7M. Revenue was up 12.2% from 2023-12-31 to 2024-12-31. IRM currently screens at market cap $37.09B and trailing P/E 135.5.
DMAC currently screens at market cap $157.4M. IRM currently screens at market cap $37.09B and trailing P/E 135.5.
Not investment advice. Open the DMAC and IRM stock pages for the full models.
Not investment advice.